Center Gallery Full Layout

Leverage agile frameworks to provide a robust synopsis for high level of overviews, iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition, at the end of the day, organically grow the world view of disruptive innovation via workplace. Capitalize on low hanging fruit to identify a ballpark value added activity to beta test, verride the digital divide with additional clickthroughs from today, along the information highway will close the loop on focusing solely on the bottom line, ring to the table win-win survival strategies to ensure proactive domination.

ClientBrandoServicesArt Direction, DesignYear2021

Privacy Preference Center

Sign Up


Please sign up here to receive email updates.

    Current reactive screening for pathogens is impractical and does not account for emerging viruses or viruses that are not screened for 7

    A proactive approach is needed to stay one step ahead. 6

    Current blood safety paradigm 7

    Maximum safety in the blood supply

    Focus on infectious disease transmission

    The precautionary principle: in the interest of public health, risk management action should be taken in the absence of certainty about risk.

    Inactivation of non-enveloped viruses by pooling and immune antibodies

    Standardized levels of neutralizing antibodies in the plasma pool minimize the risk of transmitting non-enveloped viruses (e.g., HAV, parvovirus B19, HEV).6

    • Plasma pooling1: Dilution of any initial viral load.
    • Immune neutralization2: Antibodies neutralize viral particles.
    • Chromatography: (Prion Reduction)
    • NAT testing 1: Viral levels below thresholds.

    Inactivation of non-enveloped viruses by pooling and immune antibodies


    Standardized levels of neutralizing antibodies in the plasma pool minimize the risk of transmitting non-enveloped viruses (e.g., HAV, parvovirus B19, HEV).6

    • Plasma pooling1: Dilution of any initial viral load.
    • Immune neutralization2: Antibodies neutralize viral particles.
    • Chromatography: (Prion Reduction)
    • NAT testing 1: Viral levels below thresholds.
    Tagline

    Long headline on two lines to turn your visitors into users

    Change the color to match your brand or vision, add your logo, choose the perfect layout, modify menu settings, add animations, add shape dividers, increase engagement with call to action and more.

    Feature one

    Change the color to match your brand or vision, add your logo, choose the perfect layout, modify menu settings and more.

    Feature two

    Change the color to match your brand or vision, add your logo, choose the perfect layout, modify menu settings and more.

    Inactivation of enveloped viruses by S/D treatment
    The World Federation of Hemophilia states:


    “Solvent-detergent treatment is the current gold standard for safety from the highly infectious enveloped viruses, and should be seriously considered as the option of choice when assessing products.” 3

    Inactivation of enveloped viruses by S/D treatment

    "Solvent-detergent treatment is the current gold standard for safety from the highly infectious enveloped viruses..."3

    S/D Plasma Benefits

    "Solvent/detergent treatment is gentle on plasma proteins while effective in eliminating enveloped viruses."2

    Enveloped Viruses

    Solvent/detergent reagents irreversibly disrupt the lipid membranes of all enveloped viruses (e.g., SARS-CoV-2, HIV, HBV, HCV, HGV, and CMV).4

    Log reduction factor of Octaplasma® (log10) [5]


    Filtration steps reduce allergens and cell debris.

    Standardized levels of neutralizing antibodies in the plasma pool minimize the risk of transmitting non-enveloped viruses (e.g., HAV, parvovirus B19, HEV).6

    Significant reduction of allergens

    Elimination of TRALI

    Inactivation of non-enveloped viruses by pooling and immune neutralization

    Standardized levels of neutralizing antibodies in the plasma pool minimize the risk of transmitting non-enveloped viruses (e.g., HAV, parvovirus B19, HEV).6

    • Plasma pooling1: Dilution of any initial viral load.
    • Immune neutralization2: Antibodies neutralize viral particles.
    • Chromatography: (Prion Reduction)
    • NAT testing 1: Viral levels below thresholds.

    Log reduction factor of Octaplasma® (log10) [DOF] [5]


    Adapted from Octapharma data on file.

    • HAV >8.15
    • PAROB19  >10.18
    • Prions  5.65

    Sign Up


      This website contains information that Healthcare Professionals will need to successfully transition from transfusable plasma (FP) to pathogen inactivated plasma- Octaplasma®

      I am a Canadian Healthcare Professional